New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:09 EDTCLVSClovis volatility expected to move on receiving FDA Breakthrough Therapy
Clovis Oncology volatility is expected to move after the FDA grants Breakthrough Therapy designation for CO-1686. Overall option implied volatility of 88 is above its 26-week average of 72 according to Track Data suggesting larger near term price movement.
News For CLVS From The Last 14 Days
Check below for free stories on CLVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CLVS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use